Skip to main content
Premium Trial:

Request an Annual Quote

NC Firm Buys Company, Genomics Technology to Start New Subsidiary


WILMINGTON, NC--Expanding on a major bioinformatics-related purchase earlier in the year, Pharmaceutical Product Develop ment (PPD), a contract research organization here, has announced that it is acquiring Sarco, a Durham, NC-based provider of combinatorial chemistry services, in exchange for PPD stock valued at $4.8 million. PPD is also buying the GSX System functional genomics platform technology from Ingenex, Menlo Park, Calif., for about $8.7 million in cash.

The acquisitions are aimed at allowing PPD to offer drug-discovery research services through a new wholly owned subsidiary that will be headed by former Ingenex president and CEO Mark Furth. Sarco founders Brad Brown, Eric Hallman, and Dan Ricca will serve as executive directors. In February, PPD acquired bioinformatics technologies when it bought Belmont Research, of Cambridge, Mass., which develops systems-integration technology and data management software.

"We said it makes sense to put it all together in one shop and offer seamless R&D services," said Fred Eshelman, PPD's CEO. The company has also broken ground for a 100,000-square-foot facility near Research Triangle Park that will add 175 jobs, and plans to expand its headquarters here, adding as many as 100 more positions.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.